China eyes easier regulatory nod for imported pediatric medicines

china
Regulatory

China may allow the import of more drugs that are approved for children and are already sold in Hong Kong, Macao and Taiwan as signs grow that the abandonment of its one-child policy last year may spur tweaks to pediatric medicine policies.

China's National Health and Family Planning Commission (NHFPC), China Daily reports, said 32 drugs in doses appropriate for children were placed on a list for expedited imports that could possibly be allowed without local clinical trials.

China Daily, citing the NHFPC, said that clinical studies in Hong Kong, Macao and Taiwan might be used to support approvals, which would mark a notable exception in using clinical data from outside of the country.

China has faced a persistent problem in supplying appropriate and clinically tested pediatric doses of many medicines, with doctors often prescribing modification of adult doses.

According to China Daily, the medicines under review for expedited imports cover cardiovascular, endocrine, blood and nervous system ailments and have been approved for years in the other jurisdictions.

China's one-child policy was lifted in late October, and analysts since then have pointed out that the country has a shortage of pediatric doctors and specialists as well as a lack of newer drugs in pediatric doses.

China Daily cited figures that showed that of the more than 170,000 drugs registered by China FDA by 2015, only about 3,000 had specific doses for children.

- here's the story from China Daily

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.